Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

Abstract

Clinical success of the proteasome inhibitor established bortezomib as one of the most effective drugs in treatment of multiple myeloma (MM). While survival benefit of bortezomib generated new treatment strategies, the primary and secondary resistance of MM cells to bortezomib remains a clinical concern. This study aimed to highlight the role of p53-induced RING-H2 (Pirh2) in the acquisition of bortezomib resistance in MM and to clarify the function and mechanism of action of Pirh2 in MM cell growth and resistance, thereby providing the basis for new therapeutic targets for MM. The proteasome inhibitor bortezomib has been established as one of the most effective drugs for treating MM. We demonstrated that bortezomib resistance in MM cells resulted from a reduction in Pirh2 protein levels. Pirh2 overexpression overcame bortezomib resistance and restored the sensitivity of myeloma cells to bortezomib, while a reduction in Pirh2 levels was correlated with bortezomib resistance. The levels of nuclear factorkappaB (NF-κB) p65, pp65, pIKBa, and IKKa were higher in bortezomib-resistant cells than those in parental cells. Pirh2 overexpression reduced the levels of pIKBa and IKKa, while the knockdown of Pirh2 via short hairpin RNAs increased the expression of NF-κB p65, pIKBa, and IKKa. Therefore, Pirh2 suppressed the canonical NF-κB signaling pathway by inhibiting the phosphorylation and subsequent degradation of IKBa to overcome acquired bortezomib resistance in MM cells.

Key words： bortezomib; drug resistance; multiple myeloma; NF-κB; Pirh2

References

1 Bielskiene K, Bagdoniene L, Mozuraitiene J,Kazbariene B, Janulionis E (2015) E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma. Medicina (Kaunas) 51:1–9

2 Brinkmann K, Schell M, Hoppe T, Kashkar H (2015) Regulation of the DNA damage response by ubiquitin conjugation. Front Genet 6:98

3 Cao B, Mao X (2011) The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery. Am J Blood Res 1:46–56

4 Chao A, Wang TH (2016) Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors. Taiwan J Obstet Gynecol 55:3–8

5 Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP (2012) A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22:345–358

6 Daks A, Petukhov A, Fedorova O, Shuvalov O, Merkulov V, Vasileva E, Antonov A, Barlev NA (2016) E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells. Genes Cancer 7:383–393

7 Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, Ito T, Ando H, Waldman MF, Thakurta A (2014) Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol 164:811–821

8 Goka ET, Lippman ME (2015) Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression. Oncogene 34:5395–5405

9 Hakem A, Bohgaki M, Lemmers B, Tai E, Salmena L, Matysiak-Zablocki E, Jung YS, Karaskova J, Kaustov L, Duan S (2011) Role of Pirh2 in mediating the regulation of p53 and c-Myc. PLoS Genet 7:e1002360

10 Halaby MJ, Hakem R, Hakem A (2013) Pirh2: an E3 ligase with central roles in the regulation of cell cycle, DNA damage response, and differentiation. Cell Cycle 12:2733–2737

11 Hao Z, Huang S (2015) E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy. Front Biosci (Landmark Ed) 20:474–490

12 Hou YC, Deng JY (2015) Role of E3 ubiquitin ligases in gastric cancer. World J Gastroenterol 21:786–793

13 Hsieh SC, Kuo SN, Zheng YH, Tsai MH, Lin YS, Lin JH (2013) The E3 ubiquitin ligase SIAH2 is a prosurvival factor overexpressed in oral cancer. Anticancer Res 33:4965–4973

14 Huang YH, Li SC, Huang LH, Chen PC, Lin YY, Lin CC, Kuo HC (2017) Identifying genetic hypomethylation and upregulation of toll-like receptors in Kawasaki disease. Oncotarget. 8(7):11249

15 Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZ (2012) Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol Cancer Ther 11:2243–2253

16 Jung YS, Qian Y, Chen X (2012) Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy. FEBS Lett 586:1397–1402

17 Kumar S, Rajkumar SV (2008) Many facets of bortezomib resistance/susceptibility. Blood 112:2177–2178

18 Landis-Piwowar KR (2012) Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem. Clin Lab Sci 25:38–44

19 Liu J, Shaik S, Dai X, Wu Q, Zhou X, Wang Z, Wei W (2014) Targeting the ubiquitin pathway for cancer treatment. Biochim Biophys Acta 1855:50–60

20 Lou Z, Wang S (2014) E3 ubiquitin ligases and human papillomavirus-induced carcinogenesis. J Int Med Res 42:247–260

21 Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG Jr (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343:305–309

22 Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E (2016) Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget 7:6521–6537

23 Malard F, Harousseau JL, Mohty M (2017) Multiple myeloma treatment at relapse after autologous stem cell transplantation: a practical analysis. Cancer Treat Rev 52:41–47

24 Malek E, Abdel-Malek MA, Jagannathan S, Vad N, Karns R, Jegga AG, Broyl A, van Duin M, Sonneveld P, Cottini F (2016) Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma. Leukemia. 31(3):645–653

25 Masumoto K, Kitagawa M (2016) E3 ubiquitin ligases as molecular targets in human oral cancers. Curr Cancer Drug Targets 16:130–135

26 Micel LN, Tentler JJ, Smith PG, Eckhardt GS (2013) Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol 31:1231–1238

27 Nelson JK, Cook EC, Loregger A, Hoeksema MA, Scheij S, Kovacevic I, Hordijk PL, Ovaa H, Zelcer N (2016) Deubiquitylase inhibition reveals liver X receptor-independent transcriptional regulation of the E3 Ubiquitin Ligase IDOL and lipoprotein uptake. J Biol Chem 291:4813–4825

28 Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJ, Cloos J (2015) Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat 18:18–35

29 Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T (2009) Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res 15:7153–7160

30 Petzold G, Fischer ES, Thoma NH (2016) Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4 ubiquitin ligase. Nature 532(7597):127–130

31 Rajkumar SV (2016) Myeloma today: disease definitions and treatment advances. Am J Hematol 91:90–100

32 Raninga PV, Di Trapani G, Vuckovic S, Tonissen KF (2016) TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-small ka, Cyrillicbeta inhibition. Cell Cycle 15:559–572

33 Severe N, Dieudonne FX, Marie PJ (2013) E3 ubiquitin ligasemediated regulation of bone formation and tumorigenesis. Cell Death Dis 4:e463

34 Sharma P, Nag A (2014) CUL4A ubiquitin ligase: a promising drug target for cancer and other human diseases. Open Biol 4:130217

35 Sun RC, Denko NC (2014) Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab 19:285–292

36 Tu Y, Chen C, Pan J, Xu J,Zhou ZG, Wang CY (2012) The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. Int J Clin Exp Pathol 5:726–738

37 Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM (2016) XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IkappaBalpha and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget 7:78896–78909

38 Wang G, Chan CH, Gao Y, Lin HK (2012) Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis. Chin J Cancer 31:169–177

39 Wu B, Chu X, Feng C, Hou J, Fan H, Liu N, Li C, Kong X, Ye X, Meng S (2015) Heat shock protein gp96 decreases p53 stability by regulating Mdm2 E3 ligase activity in liver cancer. Cancer Lett 359:325–334

40 Yang S, Chen Y, Sun F, Ni Q, Wang H, Huang Y,Zhang C, Liu K, Wang S, Qiu J (2016) Downregulated PIRH2 can decrease the proliferation of breast cancer cells. Arch Med Res 47:186–195

41 Yerlikaya A, Yontem M (2013) The significance of ubiquitin proteasome pathway in cancer development. Recent Pat Anticancer Drug Discov 8:298–309

42 Yin J, Zhu JM, Shen XZ (2015) The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma. Int J Cancer 136:249–257

43 Zhang J, Wan L, Dai X, Sun Y, Wei W (2014) Functional characterization of Anaphase Promoting Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis. Biochim Biophys Acta 1845:277–293

44 Zhu R, Xi H, Li YH, Jiang H, Zou JF, Hou J (2009) Establishment of a bortezomib-resistant myeloma cell line and differential proteins analysis by MALDI-OF-MS. Zhejiang Da Xue Xue Bao Yi Xue Ban 38:445–452